Across TCGA pan-cancer cohorts, IPO4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IPO4 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IPO4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IPO4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, COAD, and LSCC are the cancer types where IPO4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	25	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	OS	Quartile	II,III,IV	0.888	0.546	.023	6	view →
HNSC	DFS	Quartile	IV	0.749	1.000	.024	5	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IPO4 tumor-vs-normal RNA expression · all IPO4 data types